Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3785-3791

  Pentz, Rebecca D ^a   Flamm, Anne L ^a   Sugarman, Jeremy ^a   Cohen, Marlene Z ^a   Ayers, G Daniel ^a   Herbst, Roy S ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PHASE 1 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; CLINICAL TRIALS, PHASE I; COLLAGEN; DATA COLLECTION; DECISION MAKING; ENDOSTATINS; FEMALE; HUMANS; INFORMED CONSENT; MALE; MASS MEDIA; MIDDLE AGED; MOTIVATION; NEOPLASMS; PATIENT PARTICIPATION; PEPTIDE FRAGMENTS; PHYSICIANS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RESEARCH DESIGN;

EID: 0037106270     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.084     Document Type: Article

References (40)

1. A cautious awe greet drugs that eradicate tumors in mice
2. High hopes on cancer
3. Overdose of optimism: A case study in how a story can set off a frenzy
4. Phase I clinical trial of recombinant human endostatin in patients with solid tumors: Pharmacokinetic, safety and efficacy analysis using surrogate endpoints of tissue and radiologic response
5. Perceptions of cancer patients and their physicians involved in phase I trials
6. The impact of disease severity on the informed consent process in clinical research
7. Quality of informed consent in cancer clinical trials: A cross-sectional survey
8. Quantitative analysis of ethical issues in phase I trials: A survey interview study of 144 advanced cancer patients
9. Patients in phase I trials of anti-cancer agents in Japan: Motivation, comprehension and expectations
10. Patient motivation and informed consent in a phase I study of an anticancer agent
11. Therapeutic response in phase I trials of antineoplastic agents
12. Responses and toxic deaths in phase I clinical trials
13. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics
14. Design and results of phase I cancer clinical trials: Three-year experience at MD Anderson Cancer Center
15. Impact of the media and internet on oncology: Survey of cancer patients and oncologists in Canada
16. Importance of the lay press in the transmission of medical knowledge to the scientific community
17. Melatonin potentially useful but safety, efficacy, remain uncertain
18. Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy
19. The victims of Chernobyl in Greece: Induced abortions after the accident
20. An uneasy relationship: The tensions between medicine and the media
21. Medical scientists and health news reporting: A case of miscommunication
22. Science and the media: The boundaries of truth
23. Clinical research: What should the public believe?
24. Media wars
25. Calcium channel blockers and myocardial infarction: A hypothesis formulated but not yet tested
26. The impact of media coverage on practice
27. Attitudes toward clinical trials among patients and the public
28. Bias against negative studies in newspaper reports of medical research
29. Referral and decision making among advanced cancer patients participating in phase I trials at a single institution
30. The association between treatmentspecific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial
31. Informed consent for phase I studies: Evaluation of quantity and quality of information provided to patients
32. "Sacred" research practices we may want to change
33. Phase I cancer trials: A collusion of misunderstanding
34. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents
35. Pushing the envelope: Informed consent in phase I trials